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Background-—Autologous adipose tissue–derived mesenchymal stem cells (ATMSCs) therapy is a promising strategy to improve
post–myocardial infarction outcomes. In a porcine model of acute myocardial infarction, we studied the long-term effects and the
mechanisms involved in allogeneic ATMSCs administration on myocardial performance.
Methods and Results-—Thirty-eight pigs underwent 50 minutes of coronary occlusion; the study was completed in 33 pigs.
After reperfusion, allogeneic ATMSCs or culture medium (vehicle) were intracoronarily administered. Follow-ups were
performed at short (2 days after acute myocardial infarction vehicle-treated, n=10; ATMSCs-treated, n=9) or long term
(60 days after acute myocardial infarction vehicle-treated, n=7; ATMSCs-treated, n=7). At short term, infarcted myocardium
analysis showed reduced apoptosis in the ATMSCs-treated animals (48.66% versus 55.95.7% in vehicle; P=0.017);
enhancement of the reparative process with up-regulated vascular endothelial growth factor, granulocyte macrophage
colony-stimulating factor, and stromal-derived factor-1a gene expression; and increased M2 macrophages (67.210% versus
54.710.2% in vehicle; P=0.016). In long-term groups, increase in myocardial perfusion at the anterior infarct border was
observed both on day-7 and day-60 cardiac magnetic resonance studies in ATMSCs-treated animals, compared to
vehicle (87.928.7 versus 57.417.7 mL/min per gram at 7 days; P=0.034 and 9922.6 versus 43.314.7 22.6 mL/min
per gram at 60 days; P=0.0001, respectively). At day 60, higher vascular density was detected at the border zone
in the ATMSCs-treated animals (11818 versus 92.424.3 vessels/mm2 in vehicle; P=0.045). Cardiac magnetic
resonance–measured left ventricular ejection fraction of left ventricular volumes was not different between groups at any
time point.
Conclusions-—In this porcine acute myocardial infarction model, allogeneic ATMSCs-based therapy was associated with increased
cardioprotective and reparative mechanisms and with better cardiac magnetic resonance–measured perfusion. No effect on left
ventricular volumes or ejection fraction was observed. ( J Am Heart Assoc. 2017;6:e005771. DOI: 10.1161/JAHA.117.
005771.)
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ORIGINAL RESEARCH
S tem cell therapy has taken on the ambitious objective ofregenerating the myocardium after acute myocardial
infarction (AMI). Although complete functional regeneration
has not been achieved, diverse stem cell lineages have shown
properties that result in important beneficial effects in the
infarcted myocardium.1–4 In this context, adipose tissue–
derived mesenchymal stem cells (ATMSCs) have shown
remarkable outcomes in small-animal studies,5–7 ameliorating
adverse cardiac remodeling and improving ventricular function
and myocardial vascularization. These findings could be
related to secretion of anti-apoptotic, pro-angiogenic, and
anti-inflammatory cytokines and growth factors. Some of
these therapeutic mechanisms have been described in vitro
and using small-animal models,8–10 but no experiments in
large animals have evaluated the early mechanisms involved
in the long-term outcomes.
Moreover, although our group has reported better benefits
of ATMSCs intracoronary administration immediately after the
reperfusion,11 the ideal dosage, route, and timing for cell
administration remains unresolved.12 Furthermore, as AMI is
unpredictable, allogeneic stem cells must always be immedi-
ately available when needed. Preclinical studies13 and the
POSEIDON (Percutaneous Stem Cell Injection Delivery Effects
on Neomyogenesis) trial14 have found allogeneic cell delivery
to be as safe and effective as therapies using autologous
sources. Nevertheless, long-term cardiac benefits of allo-
geneic ATMSCs therapy on reperfused hearts must be studied
at length in large-animal models of AMI before the treatment
can advance to the clinical phase.
Therefore, the aim of the present study was to analyze the
short- and long-term effects of allogeneic ATMSCs therapy on
immune response, myocardial vascularization, and cardiac
function and perfusion assessed by cardiac magnetic reso-
nance (CMR), as well as the mechanisms involved, in a
translational porcine model of AMI.
Methods
The study protocol was approved by the Animal Experimen-
tation Ethics Committee of the National Center for Cardio-
vascular Research (Spanish acronym, CNIC) following the
Communities Council Directive 2010/63/UE and Spanish (RD
53/2013) regulations related to the Guide for the Care and
Use of Laboratory Animals.
Study Design
A total of 41 Large White pigs were used in this study. Three
male pigs (56.52.2 kg; 5–6 months old) served as adipose
tissue donors and 38 female pigs (35.12.7 kg; 3–4 months
old) underwent a reperfused AMI after 50-minute occlusion of
the left anterior descending (LAD) coronary artery. Four
animals died during the procedure; the 34 remaining animals
were randomized into experimental (ATMSCs-treated) and
control (vehicle-treated) groups stratified by follow-up: short-
term follow-up (2 days post-AMI), ATMSCs (n=10) and vehicle
(n=10); and long-term follow-up (60 days post-AMI), ATMSCs
(n=7) and vehicle (n=7). One ATMSCs animal assigned to
short-term follow-up was excluded from analysis because of
incomplete reperfusion attributable to technical failure, leav-
ing 9 animals in this group and a total of 33 animals in the
analysis (Figure 1A). Protocol timelines for molecular, imag-
ing, and histological analysis are summarized in Figure 1B.
Subcutaneous Adipose Tissue Collection and Cell
Isolation, Culture, and Labeling
Subcutaneous adipose tissue from donor animals was excised
from the ventral neck area and kept at 4°C in phosphate-
buffered saline (Sigma-Aldrich, St. Louis, MO) supplemented
with 1% penicillin/streptomycin (Gibco, Grand Island, NY). Cells
were isolated and cultured as described previously.11,15 The
cells were expanded in a-minimal essential medium (Sigma-
Aldrich) supplemented with 10% fetal bovine serum, 1 mmol/L
L-glutamine, and 1% penicillin/streptomycin (Gibco), and 5 lg/
mL PlasmocinTM (Invitrogen) under standard culture conditions
(37°C, 5% CO2), with medium replacement every 3 days. Third-
passage cells were labeled by transduction (29106 transduc-
ing units/mL multiplicity of infection=21, 48 hours) with a
lentiviral vector containing enhanced green fluorescent protein
(GFP) under constitutive transcriptional control.16 Cells
expressing GFP were selected by fluorescence-activated cell
sorting and frozen before in vivo administration.
AMI Procedure and Intracoronary Administration
The same day of the intervention, animals received oral
clopidogrel (150 mg/animal). Antiaggregant therapy was
continued 2 days after the AMI induction (clopidogrel
75 mg/animal per day). Anesthesia was induced by an
intramuscular injection of ketamine (20 mg/kg), xylazine
(2 mg/kg), and midazolam (0.5 mg/kg) and maintained with
continuous intravenous infusion of ketamine (2 mg/kg per
hour), xylazine (0.2 mg/kg per hour), and midazolam
(0.2 mg/kg per hour) and by analgesia with intravenous
fentanyl (0.007 mg/kg per hour). Animals were intubated and
supportive mechanical ventilation was maintained during the
AMI procedure. Sheaths (6F) were percutaneously placed in
the femoral artery and vein for drug administration and blood
collection, and a heparin bolus of 9000 IU was given before
coronary catheterization. AMI was then induced as previously
described.17–19 Briefly, the LAD was cannulated with a 5F
guide catheter, by which a coaxial balloon catheter was
advanced past the first diagonal branch. Once placed, the
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balloon was inflated at low pressure and ischemia was
maintained for 50 minutes. LAD occlusion was confirmed
angiographically. During ischemia, a continuous infusion of
amiodarone (5.5 mg/kg per hour) was administered to
prevent malignant ventricular arrhythmias. A biphasic defib-
rillator was used in case of ventricular fibrillation episodes.
After 50 minutes occlusion, the balloon was deflated. Fifteen
minutes after reperfusion, 107 ATMSCs suspended in 14 mL of
Dulbecco’s Modified Eagle Medium or Dulbecco’s Modified
EagleMediumwithout cells, depending on the study group, were
administered through the coaxial catheter. In order to minimize
ischemia during the intracoronary delivery, 7 boluses of 2 mL
(1 mL/min) Dulbecco’sModified EagleMediumwith the balloon
inflated were interspersed with 2-minute periods of blood flow
restoration with the balloon deflated.
Cardiac Imaging Studies
All cardiac imaging studies were performed with the animals
under anesthesia. In the short-term follow-up groups, a
computed tomography (CT) 64-slice scanner (Brilliance iCT;
Philips Medical Systems, Best, The Netherlands) was used to
evaluate LAD patency before euthanizing the animals (Fig-
ure 1B). Analysis of CT images was performed on a dedicated
advanced image processing workstation (Extended Brilliance
Workspace 3.5; Philips Medical Systems, Cleveland, OH) by 2
independent blinded investigators using mainly multiplanar
reconstructions. In the long-term follow-up groups, CMR study
was performed at 7 and 60 days (Figure 1B) with an Achieva
3T-TX whole-body scanner (Philips Healthcare, Best, The
Netherlands) equipped with a 32-element phased-array
Figure 1. Flow chart illustrating the study design (A) and timeline (B). AMI indicates acute myocardial
infarction; ATMSCs, adipose tissue-derived mesenchymal stem cells; CMR, cardiac magnetic resonance; CT,
computed tomography; LAD, left anterior descending coronary artery.
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cardiac coil as previously described.20 Each study consisted
of a cine steady-state free-precision sequence to determine
left-ventricular end-diastolic volume, left-ventricular end-
systolic volume, and left ventricular ejection fraction21; late
gadolinium-enhanced sequence to determine infarct size and
microvascular obstruction (MVO); and (only at the 7-day CMR)
a T2-weighted short-tau inversion recovery sequence to
determine the extent of myocardial edema.21 Absolute
cardiac perfusion was estimated using dynamic acquisition
with dual-saturation (TS=20, 80 ms) technique to avoid signal
saturation during gadolinium-based contrast administration.22
After perfusion maps generation, region-of-interest analysis
was done at the infarcted core, infarct borders (anterior wall
and septum), and remote myocardium.
Images were analyzed by 2 independent blinded investi-
gators, and processed with analysis software (QMass MR 7.5;
Medis, Leiden, The Netherlands and MR Extended Work Space
2.6; Philips Healthcare) as previously described.21 In case of
lack of agreement between the conclusions of the 2
investigators, the discordant images were reviewed by a third
blinded investigator.
Assessment of Circulating Cytokines and Donor-
Specific Antibodies
In the short-term follow-up groups, blood samples were
obtained at baseline before AMI induction and at 2 days post-
AMI. In the long-term follow-up groups, blood sampling was
carried out at baseline and at 7, 21, and 60 days post-AMI
(Figure 1B). In a randomized subset of animals (short-term
follow-up groups, 7 vehicle and 8 ATMSCs-treated; long-term
follow-up groups, 5 vehicle and 5 ATMSCs-treated), serum
quantification of interleukin-10 (IL-10) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) was per-
formed with the cytokine multiplex assay (Quantibody
Porcine Cytokine Array 1; RayBiotech, Norcross, GA). In
addition, circulating levels of stromal-derived factor-1a (SDF-
1a) and hepatocyte growth factor (HGF) were assessed in 5
animals from each of the 4 groups using pig SDF-1a and HGF
ELISA kits, respectively (Cusabio Biotech, Wuhan, China). All
protocols were performed according to manufacturer instruc-
tions. To analyze antibody-mediated rejection, crossmatch
tests were performed on serum samples from ATMSCs-
treated animals in the long-term follow-up group at 21 and
60 days, as previously described.11
Tissue Harvesting
At 2 (short-term follow-up groups) or 60 days (long-term
follow-up groups), animals were euthanized and hearts were
harvested (Figure 1B). Hearts were cut into transversal slices
and representative sections were obtained from the anterior
core infarcted wall, septum and anterior border zones, and
remote posterior wall of the left ventricle. Tissue samples
were fixed with 4% formaldehyde and embedded in paraffin for
histological studies as previously reported.15 Tissue samples
for molecular biology studies were maintained in Allprotect
Tissue Reagent (Qiagen, Hilden, Germany) until storage at
80°C. Samples were also collected from lung, thoracic
lymphatic nodes, liver, jejunum, spleen, and kidney for
histological and molecular analysis to track delivered GFP-
ATMSCs.
Histology
Histological analysis was performed on 4-lm sections of
paraffin-embedded specimens. ATMSCs retention in the
infarcted myocardium and border zones was determined by
immunofluorescence, using chicken anti-GFP (1:1000,
ab13970; Abcam, Cambridge, MA) and cardiac troponin I
(1:200, sc-15368, Santa Cruz Biotechnology, Santa Cruz, CA)
as primary antibodies.
Apoptotic cells in the infarcted tissue and border zones
were stained with terminal deoxynucleotidyl transferase TdT-
mediated dUTP nick-end-labeling technique using the In Situ
Cell Death Detection Kit, Fluorescein (Roche Applied Science,
Indianapolis, IN) according to manufacturer instructions.
Vascular density was assessed by double immunohistochem-
istry with anti-vonWillebrand factor (1:200, A0082; Dako,
Carpinteria, CA) and anti-smooth muscle actin (1:100,
M085101; Dako) antibodies.11 Small vessels (<15-lm diam-
eter) were counted in the border zones. Inflammatory cellular
infiltration was studied in the infarct and border zones by
detection of lymphocytes T with anti-CD3 (1:100, M0701;
Dako),11 total macrophages with CD107a (1:100,
MCA2315GA; Bio-Rad, Kidlington, UK), and the M2-polarized
subgroup with CD163 (1:100, bs2527R; Bioss, Beijing, China)
antibodies. Collagen deposition in the remote area and the
infarct zone was determined by picrosirius red staining.
Stained samples from the infarct zone were also analyzed with
circularly polarized light to determine collagen I and III.
All histological analyses were performed by 2 independent
blinded investigators.
Quantitative Real-Time Polymerase Chain
Reaction
mRNA expression of GFP, IL-10, HGF, GM-CSF, SDF-1a,
vascular endothelial growth factor (VEGF), hepatocyte growth
factor receptor, extracellular signal–regulated kinase 1, and
secreted frizzled-related protein 2 were determined in the
central infarct zone by quantitative real-time polymerase
chain reaction (qPCR), based on SYBR Green fluorescence as
previously described.23 qPCR was performed using the ViiATM
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7 Real-Time PCR System (Applied Biosystems, Foster City,
CA). Primer sequences used are described in Table 1.
Real-Time PCR for GFP mRNA Quantification
The GFP mRNA in infarcted myocardium and border zones
was quantified using SYBR Green–based real-time PCR
protocol. Reverse-transcribed GFP cDNA was amplified,
starting with 100 ng of total cDNA and using the primer pair
50-AAGTTCATCTGCACCACCG0-30 (GFP-Forward) and 50-
TCCTTGAAGAAGATGGTGCG-30 (GFP-Reverse). Number of
GFP transcript copies was established by comparison to a
calibration curve based on known amounts of GFP DNA from
GFP expression control vector (pLenti6.2-GW/EmGFP; Invit-
rogen, Waltham, MA). The standard curve for GFP DNA was
obtained by 10-fold serial dilution from 1 ng (39106 copy
number of GFP) to 1 fg (3 copy number of GFP) of the GFP
expression control vector (Figure 2). A concomitant quantifi-
cation of b-Actin mRNA (input and reverse transcription
control) was performed for each experimental sample.
Statistical Analysis
SPSS software (IBM SPSS Statistics for Windows, Version
23.0, released 2013; IBM Corp, Armonk, NY) was used to
perform statistical analysis and GraphPad Prism (version 5.00
for Windows; GraphPad Software, San Diego, CA) to create
the graphics dots. Normal distribution was assessed with the
Kolmogorov–Smirnov test and confirmed by visually checking
the distribution of the variables. Continuous normal dis-
tributed variables were studied with the t test and are
represented as meanSD; non-Gaussian continuous variables
were assessed by Mann–Whitney test and represented as
median and [interquartile range] (25th–75th percentiles).
Qualitative variables (mortality) were compared using the
Fisher exact test. Time-dependent comparisons of CMR-
derived myocardial perfusion obtained at day 7 and day 60
within each group were studied with paired t test. Linear
regression of standard curve obtained from serial dilutions of
the pLenti6.2-GW/EmGFP plasmid was used to calculate GFP
mRNA quantification by real-time PCR.
Results
AMI Procedure and Mortality
At 2 days post-AMI, LAD angiography revealed occlusion,
induced by a technical failure, in only 1 of the 20 animals
assessed by CT. This animal was excluded from analyses.
During the first 48 hours after AMI induction, 4 animals died
Table 1. Primer Sequences for Quantitative RT-PCR
Gene Oligo Name Oligo Sequence (50 to 30)
CSF2 (NM_214118.2 ) GM-CSF Forward GGATTGCTCCCACTGACAGA
GM-CSF Reverse GCAAGTCTGTGCCCCATTAC
IL-10 (NM_214041.1 ) IL10 Forward GGGAAACCCTGCTGTACCTC
IL10 Reverse TGAACACCATAGGGCACACC
SDF-1a (NM_001009580.1 ) SDF-1a Forward CCGAACTGTGCCCTTCAGAT
SDF-1a Reverse ATAAACATCCCGCCGTCCTC
HGF (XM_013979787.1 ) HGF Forward TGCTCCTCCCTTCCCTACTC
HGF Reverse CCCGATAGCTCGAAGGCAAA
VEGF (AF318502.1 ) VEGF Forward CCACGAAGTGGTGAAGTTCATG
VEGF Reverse CCACCAGGGTCTCGATTGG
MET (NM_001038008 ) HGFR Forward CAGAAGAGCAAGGGAGAGTGT
HGFR Reverse GGGCACCCAGGTAAATGTGAT
MAPK3 (XM_013991188.1 ) ERK-1 Forward GGCTCATCCTTACCTGGAGC
ERK-1 Reverse AGATGAGTTCCTTCAGCCGC
SFRP2 (NM_001244395.1 ) SFRP-2 Forward CCCGACTTCTCCTACAAGCG
SFRP-2 Reverse GCCGCATGTTCTGGTACTCT
ACTB (XM_003124280.4 ) b-Actin Forward GTGACAGCAGTCGGTTGGAT
b-Actin Reverse TTTTGGGAAGGCAGGGACTT
ACTB indicates actin beta; CSF, colony-stimulating factor; HGF, hepatocyte growth factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-10, interleukin-10; MAPK3, mitogen-
activated protein kinase 3; MET, MET proto-oncogene; RT-PCR, reverse transcription polymerase chain reaction; SDF-1a, stromal-derived factor-1a; SFRP2, secreted frizzled-related protein 2.
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(10.5%, without significant differences between study groups)
(Figure 1A). One animal (ATMSCs group) died during AMI
induction because of malignant arrhythmia. Three more
animals (1 from control group, 2 from ATMSCs group) died
post-AMI in the animal facilities, presumably because of
malignant arrhythmia related to AMI.
Effectiveness and Safety of Cell Delivery
Myocardial ATMSCs engraftment after intracoronary adminis-
tration was evaluated by GFP tissue detection in the short-term
(2 days) and long-term (60 days) groups. Immunohistochem-
ical analysis showed 43 GFP-positive cells per histological
section both in the infarcted myocardium and border zone at
2 days post-AMI (Figure 3). GFP expression was also detected
by qPCR in the infarcted tissue (21.1712.0 copies of GFP) and
moremarkedly in the border zone (96.0735.7 copies of GFP).
Moreover, 30.9% of the observed GFP-positive cells were
terminal deoxynucleotidyl transferase TdT-mediated dUTP nick-
end-labeling–positive. In the long-term groups, we found no
GFP-positive cells in the histological study and detected no GFP
gene signal by qPCR. No sign of engrafted GFP-positive cells
was detected in remote organs in any group.
Inflammatory infiltration was evaluated by histological
analysis at 2 days in the short-term groups and at 60 days
in the long-term groups. Table 2 shows the number of
lymphocytes T and macrophages found in the infarcted
myocardium and at the border zone. No significant differences
were observed between groups. However, at 60 days, an
elevated number of T lymphocytes was observed in 2 animals
(483.6 and 1085.5 CD3-positive cells/mm2) receiving
ATMSCs, and 1 of them was also crossmatch test positive
for humoral immunity. No donor-specific antibodies in serum
were found in the other 6 animals receiving allogeneic
ATMSCs at 60 days post-AMI.
No coronary artery vasospasm was detected while admin-
istering the ATMSCs. MVO was assessed by CMR in the long-
term follow-up groups at 7 days post-AMI as safety end point.
No significant differences were observed between vehicle
animals and those receiving ATMSCs (6.08.1% versus
6.27.2% of infarct, respectively; P=0.960).
Vascular Density
Vascular density was similar in both short-term follow-up
groups (49.19.1 in vehicle versus 57.115.1 <15-
lm vessels/mm2 in ATMSCs; P=0.176). In contrast, in the
long-term follow-up groups, a significant increase in small
vessels was detected in the infarct border zones of animals
treated with ATMSCs, compared with vehicle-treated
(11818 versus 92.424.3 <15-lm vessels/mm2, respec-
tively; P=0.045) (Figure 4A).
Cardiac Function, Edema, Infarct Tissue, and
Perfusion by CMR Imaging
CMR values from the long-term follow-up groups are summa-
rized in Table 3. At 7 days, no statistical differences were
observed between vehicle and ATMSCs groups in the infarct
size normalized by edema extent, as determined by CMR
(0.960.04 versus 0.950.06, respectively; P=1.000). At 60-
day follow-up, scar size was also similar between vehicle and
ATMSCs-treated animals (19.14.3% versus 15.44.7% of
left ventricle, respectively; P=0.153) (Figure 5).
Left ventricle functionality study showed no significant
differences between groups at 7 or at 60 days in terms of left-
ventricular end-diastolic volume, left ventricular end-systolic
volume, or left-ventricular ejection fraction. Myocardial perfu-
sion of the anterior infarct border was significantly higher
7 days after the intervention in the animals treated with
ATMSCs, compared with the vehicle group (87.928.7 versus
57.417.7 mL/min per gram, respectively; P=0.034). This
difference was remarkably higher at 60 days post-AMI
(9922.6 versus 43.314.7 mL/min per gram; P=0.0001)
(Figure 4B).
Mechanisms Involved in ATMSCs Effects
Pro-angiogenic factors
The studies of pro-angiogenic mechanisms revealed a
higher expression of SDF-1a and GM-CSF genes in the
infarcted tissue of ATMSCs-treated animals, compared with
Figure 2. Linear regression of standard curve obtained from
serial dilutions of the pLenti6.2-GW/EmGFP plasmid (3—
39106 copy number) assayed in duplicate by qPCR. R2 and
equation of linear regression are described in the intersection point
of the chart. Ct indicates threshold cycle; GFP, green fluorescent
protein; qPCR, quantitative real-time polymerase chain reaction.
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vehicle-treated, at 2 days. VEGF was also augmented in
the infarct zone in the ATMSCs group (Figure 4C). Never-
theless, at 60 days, no significant differences in SDF-1a,
VEGF, and GM-CSF genes expression were observed
among groups.
Analysis of circulating pro-angiogenic factors in the serum
showed a significant increase in GM-CSF at 2 days post-AMI
in animals treated with ATMSCs, compared with vehicle
(1.691.08 versus 0.050.62 log2 fold change, respectively;
P=0.003). However, decreased GM-CSF was detected in
serum of ATMSCs-treated animals, compared with vehicle-
treated, at 7 (0.320.32 versus 0.350.15 log2 fold
change, respectively; P=0.003) and 60 days (0.930.81
versus 1.150.93 log2 fold change, respectively; P=0.006).
A
B
Figure 3. ATMSCs implantation in the myocardium. Confocal microscopy images showing GFP-positive
ATMSCs (green) in the infarct area (A) and border zone (B) (cTnI in white and nuclei counterstained with
DAPI in blue). Right panels represent zoom images from the left panels. Scale bars, 50 lm. ATMSCs
indicates adipose tissue-derived mesenchymal stem cells; cTnI, cardiac troponin-I; DAPI, 40,6-diamidino-2-
phenylindole dihydrochloride; GFP, green fluorescent protein.
Table 2. CD3-Positive Cells (Lymphocytes T) and CD107a-Positive Cells (Macrophages) per mm2 of Myocardium
Short-Term Follow-Up Long-Term Follow-Up
Vehicle (n=10) ATMSCs (n=9) P Value Vehicle (n=7) ATMSCs (n=7) P Value
T lymphocytes 202.690 206.461.5 0.916 141.848.1 345.9352.6 0.155
Macrophages 1383.7407.6 1451.8401 0.718 42.718.8 59.820.2 0.126
Values are represented as meanSD. ATMSCs indicates adipose tissue-derived mesenchymal stem cells.
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Figure 4. Effects of ATMSCs therapy on myocardial vascularization and perfusion. A,
Microphotographs on the left (endothelial cells stained in brown and smooth muscle cells
stained in red) and bar chart on the right showing increased vessel density in the border infarct
zone of animals receiving cell therapy. B, Bar chart on the left and cardiacmagnetic resonance
images (myocardial quantitative perfusion maps) on the right illustrate an enhancement on
myocardial perfusion of infarct border zone in animals receiving allogeneic ATMSCs. Arrows
point to perfusion analysis region of interest (gray, anterior infarct border; white, core infarcted
area; black, septum infarct border; yellow, posterior remote myocardium). C, Charts show up-
regulation of the pro-angiogenic mediators SDF-1a, GM-CSF, and VEGF in the infarcted tissue
of the ATMSCs group compared with vehicle group, as assessed by qPCR. *P<0.05 between
groups; **P<0.01 between groups; §P<0.05 paired t test. Scale bars, 50 lm. ATMSCs
indicates adipose tissue-derived mesenchymal stem cells; GM-CSF, granulocyte-macrophage
colony-stimulating factor; qPCR, quantitative real-time polymerase chain reaction; SDF-1a,
stromal-derived factor 1a; VEGF, vascular endothelial growth factor.
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Dynamics of circulating SDF-1a were similar between groups
at short- and long-term follow-up (Figure 6).
Anti-apoptotic effects
The percentage of apoptotic cells in the infarct zone was
significantly lower in the ATMSCs-treated animals compared
with vehicle at 2 days post-AMI (48.66% versus 55.95.7%,
respectively; P=0.017). No differences between groups were
observed in the border zone (Figure 7A). Study of anti-
apoptotic pathways showed a significant increase in circulat-
ing HGF levels in the ATMSCs group (Figure 7B). Moreover,
hepatocyte growth factor receptor, extracellular signal–regu-
lated kinase 1, and secreted frizzled-related protein 2 genes
were up-regulated in the infarcted myocardium of ATMSCs-
treated animals (Figure 7C). At 60 days, there were no
differences in hepatocyte growth factor receptor, extracellular
signal–regulated kinase 1, and secreted frizzled-related pro-
tein 2 genes expression between vehicle and ATMSCs groups.
HGF gene expression was similar at 2 and 60 days post-AMI
in the infarcted tissue of both vehicle and ATMSCs-treated
animals. The long-term follow-up groups were also similar in
their circulating HGF dynamic (Figure 7B).
Anti-inflammatory mechanisms
The analysis of possible anti-inflammatory mechanisms at
2 days post-AMI showed a significantly higher percentage of
alternatively activated M2 (CD163-positive) macrophages with
respect to total number of (CD107a-positive) macrophages in
the infarct zone of ATMSCs-treated animals, compared with
vehicle-treated (67.210% versus 54.710.2%, respectively;
P=0.016) (Figure 8A). A higher expression of IL-10 gene was
observed in the infarcted tissue of ATMSCs animals, compared
with vehicle, in the short-term follow-up groups. Moreover, this
anti-inflammatory cytokine (IL-10) was increased at 2 days in
systemic blood of animals treated with ATMSCs (Figure 8B). In
the long-term follow-up groups, a significant increase in the
circulating IL-10 was found in the ATMSCs group only at 60-day
follow-up (0.992.67 versus vehicle, 3.643 log2 fold
change, respectively; P=0.032). Nevertheless, no significant
differenceswere observed in the expression of IL-10 gene in the
infarcted tissue (Figure 8C).
Effect on collagen deposition
Histological assessment of left ventricle remodeling at
60 days showed no differences in collagen deposition in the
remote zone between vehicle and ATMSCs groups (6.31%
versus 6.60.6% of area, respectively; P=0.525) or at the scar
(38.810.6% versus 41.78.7% of area, respectively;
P=0.597). Nevertheless, the collagen type I/type III ratio of
the scar was significantly higher in ATMSCs-treated animals,
compared with vehicle (1.50.2% versus 2.40.7% of area,
respectively; P=0.010) (Figure 9).
Discussion
The present study analyzed the long-term outcomes and
potential mechanisms of allogeneic ATMSCs therapy in a
translational porcine model of reperfused AMI. The main
Table 3. CMR Results
7 Days Post-AMI 60 Days Post-AMI
Vehicle (n=7) ATMSCs (n=7) P Value Vehicle (n=7) ATMSCs (n=7) P Value
LVEDV, mL 133.217.0 133.422.6 0.986 201.337.3 190. 637.2 0.600
LVESV, mL 80.316.9 74.315.9 0.510 126.535.8 110.630.4 0.387
LVEF, % 40.25.2 44.43.6 0.110 37.96.3 42.75.2 0.142
Infarct size (% LV) 30.85.5 25.05.0 0.061 19.14.3 15.44.7 0.153
MVO (% infarct) 6.27.2 6.08.1 0.960 — — —
Edema (% LV) 32.15.4 26.34.9 0.059 — — —
Infarct size (% edema) 0.960.04 0.950.06 1.000 — — —
Myocardial perfusion, mL/min per gram
Core infarcted area 52.735.0 45.622.9 0.658 64.516.7 69.819.6 0.618
Anterior infarct border 57.417.7 87.928.7 0.034 43.314.7 99.022.6 <0.001
Septum infarct border 65.526.6 71.914.8 0.588 60.63.7 76.230.1 0.237
Posterior remote wall 214.373.3 212.576.8 0.965 120.23.7 179.387.5 0.118
Values are represented as meanSD. Edema sequences and MVO were only available at the 7-day CMR study.18 AMI indicates acute myocardial infarction; ATMSCs, adipose tissue-
derived mesenchymal stem cells; CMR, cardiac magnetic resonance imaging; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV,
left ventricular end-systolic volume; MVO, microvascular obstruction.
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finding of our work was that allogeneic ATMSCs administra-
tion promoted an increase in myocardial perfusion in the
ischemic tissue of animals with AMI. Moreover, a decrease in
the apoptotic process and an up-regulation of anti-inflamma-
tory and reparative mechanisms have been identified in the
short-term after ATMSCs administration.
Intracoronary Delivery of Allogeneic ATMSCs
Intracoronary administration is one of the least invasive
delivery methods, although infusion of large-size adult mes-
enchymal stem cells (MSCs) (up to 20 lm in diameter) could
potentially obstruct capillaries (from 6 to 10 lm in diameter),
leading to permanent no-reflow phenomena after cell admin-
istration. In this sense, clinical24 and preclinical25–29 studies
have found that intracoronary injection of a significant
number (up to 50 million) of large-size stem cells (20–
50 lm in diameter) can be safe when administered a few days
after AMI. However, microvascular injury is higher during the
first 24 hours post-AMI, and therefore the probability of
capillary plugging and MVO increases when administering
large cells directly into the culprit artery. Although MVO
persists at least 1 week after reperfusion,30 our study found
no MVO increase at 7 days post-AMI in those animals
receiving 107 ATMSCs (13 lm in diameter) in the LAD just
after reperfusion. Our finding agrees with most of the previous
literature11,27,31 and supports the feasibility and safety of
intracoronary administration of large-size cells just after
reperfusion as long as precautions are taken in determining
the infusion rate and dose.
The protocol of cell administration just after reperfusion
requires rapid availability of ATMSCs; the cells must be stored
to use when needed and, consequently, allogeneic origin is
required. An important advantage of administering allogeneic
stem cells is that they could be obtained from healthy young
donors, since quantitative and qualitative stem cell deterio-
ration has been demonstrated in aged patients32 with
atherosclerotic risk factors.33
Host Response
Originally, MSCs were described as possessing an immuno-
privileged status and immunosuppressive properties,34 which
could present an advantage for allogeneic cell therapies. In
our porcine model, no significant differences between groups
were observed in immune cells infiltration after cell therapy;
however, 2 animals receiving allogeneic ATMSCs had
increased T-lymphocyte infiltration at 60 days, which could
Figure 5. Late gadolinium-enhanced CMR images. Follow-up CMR analysis showed similar infarct size
between controls and ATMSCs-treated animals at 7 and 60 days. Red dashed lines depict late gadolinium-
enhanced infarcted myocardium. ATMSCs indicates adipose tissue-derived mesenchymal stem cells; CMR,
cardiac magnetic resonance.
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reflect interindividual variations in the response. Moreover,
only 1 of the 7 animals receiving allogeneic ATMSCs produced
allo-antibodies, which agrees with the host response observed
in our previous study in the same animal model11 and a
previously reported clinical trial14 using allogeneic MSCs.
Conversely, Kanazawa35 reported the absence of humoral
rejection after in vivo administration of allogeneic cardio-
sphere-derived cells, which could be explained by differences
in source-dependent characteristics described by Ock et al.36
Insights Into ATMSCs Modulation of Endogenous
Reparative Process and Inflammatory Response
Two days after administration, one third of implanted ATMSCs
were already in apoptosis and no signal of ATMSCs presence
was detected in the infarcted tissue at long-term follow-up.
Nevertheless, major benefits after ATMSCs therapy were
observed at 60 days, suggesting that the long-term benefits
observed in our study are a consequence of changes
promoted by ATMSCs in the acute phase after their admin-
istration. To test this hypothesis, we evaluated some of the
mechanisms involved in the repair process and stimulation of
endogenous stem cell population. In particular, we found an
increase in the chemotactic mediators SDF-1a and GM-CSF at
2 days after cell administration. As previously proposed,11,37
we would further hypothesize that endogenous stem cell
stimulation could increase and continue to support the
regenerative mechanisms promoted by MSC therapy, even
when these cells were not present in the infarcted tissue.
Accordingly, ATMSCs administration could be described as a
booster therapy for the endogenous reparative process. In
addition, a qualitative modification to the percentage of anti-
inflammatory and pro-repair M2 macrophages was detected in
our porcine model of AMI. A relationship between ATMSCs
and polarization of M2 macrophages has been previously
described in vitro38 and in a porcine model of renal artery
stenosis.39 Our finding was also accompanied by a clear
increase in circulating IL-10 and its mRNA in the infarcted
tissue in the short term after ATMSCs administration. One of
the most important anti-inflammatory mediators, IL-10 is
involved in the pro-inflammatory/anti-inflammatory macro-
phages switch and, therefore, in setting up the reparative
phase.40
ATMSCs Administration as a Pro-Vascularization
Therapy
Improved vascular density15,31,41 and myocardial perfu-
sion27,31 have been reported after autologous ATMSCs
therapy. In our study, similar outcomes were found but after
intracoronary administration of ATMSCs from allogeneic
origin. Moreover, we identified an enhancement of 4 medi-
ators (VEGF, HGF, GM-CSF, and SDF-1a) and M2 macro-
phages involved in neovascularization in the acute phase after
cell administration as potential mechanisms in the improve-
ment of myocardial perfusion. Our data suggest that these up-
regulated pro-angiogenic mechanisms just 2 days after
therapy could have an important role in the increase of
Figure 6. Bar charts represent SDF-1a in serum in the short-term follow-up (A) and long-term follow-up (B)
groups. ATMSCs indicates adipose tissue-derived mesenchymal stem cells; SDF-1a, stromal-derived factor 1a.
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Figure 7. Analysis of apoptotic process. A, On the left, images from immunofluorescent staining
(TUNEL-positive nuclei stained in magenta and total nuclei counterstained with DAPI in blue) and on
the right, bar chart comparing study groups’ percentage of apoptotic cells in the infarcted tissue and
border infarct zone at 2 days post-AMI. B, Bar chart on the left showing an increase in the anti-
apoptotic mediator HGF in serum of ATMSCs-treated animals, as measured by ELISA technique. Bar
charts on the right show similar dynamics of HGF in the long-term follow-up groups. C, Box plots
represent gene expression by qPCR of HGFR and ERK-1, mediators of HGF signaling pathway, and the
anti-apoptotic SFRP-2 up-regulation in infarcted tissue of ATMSCs group animals. *P<0.05 between
groups. Scale bars, 50 lm. ATMSCs indicates adipose tissue-derived mesenchymal stem cells; AMI,
acute myocardial infarction; DAPI, 40,6-diamidino-2-phenylindole dihydrochloride; ERK-1, extracellular
signal–regulated kinase 1; HGF, hepatocyte growth factor; HGFR, hepatocyte growth factor receptor;
qPCR, quantitative real-time polymerase chain reaction; SFRP-2, secreted frizzled-related protein 2;
TUNEL, terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end-labeling.
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Figure 8. ATMSCs modulatory properties on inflammatory response. A, Microphotographs on the left show
macrophages (CD107a-positive cells in red) and the M2 macrophages subset (CD163-positive and CD107a-
positive cells, double stained in green and red) in the infarct zone. Bar chart, on the right, shows higher
percentage ofM2macrophageswith respect to total macrophages in ATMSCs group comparedwith vehicle. B,
Anti-inflammatory IL-10 was found up-regulated in the infarcted tissue by qPCR (bar chart on the left) and
increased in serum by ELISA (bar chart on the right) in animals receiving ATMSCs, compared with vehicle-
treated at 2 days post-AMI. C, Bar chart on the left shows IL-10 gene expression assessed by qPCR in the long-
term follow-up groups. The study of circulating IL-10 showed similar dynamics at 7- and 21-day follow-up in
both study groups; however, a significant increase of IL-10 in serum was detected at 60 days post-AMI in
ATMSCs-treated animals compared with controls (bar charts on the right). *P<0.05 between groups. Scale
bars, 20 lm. ATMSCs indicates adipose tissue-derived mesenchymal stem cells; DAPI, 40,6-diamidino-2-
phenylindole dihydrochloride; IL-10, interleukin-10; qPCR, quantitative real-time polymerase chain reaction.
DOI: 10.1161/JAHA.117.005771 Journal of the American Heart Association 13















myocardial perfusion observed at 7-day follow-up. Given the
observed trend toward better myocardial perfusion at
60 days, compared to 7 days, we hypothesize that the
increase in the pro-angiogenic mediators promoted by
ATMSCs therapy not only enhances the initial physiological
vessel sprout but also contributes to maintain this newly
established microvasculature. In contrast, we observed a
significant decrease in myocardial perfusion at 60-day follow-
up in the vehicle group, suggesting a certain loss of the new
microvasculature established in the acute post-AMI phase. In
this sense, the decrease in the apoptotic process observed
after 2 days and propitiated by the ATMSCs therapy could
also have an important role in promoting vessel persistence in
ATMSCs-treated animals, enhancing vessel density and
myocardial perfusion in the longer term.
Our main findings about myocardial vascularization and
perfusion could have clinical implications for improving the
patient’s quality of life, as in the PROGENITOR trial.3 The
earlier clinical study showed an enhancement in myocardial
perfusion together with a decrease in the number of angina
episodes and improved angina functional class in patients
who had refractory angina and who received a transendocar-
dial injection of CD133+ progenitor cells.
Cardiac Function and Remodeling
Despite the lack of any reduction in infarct size or improve-
ment in left ventricular ejection fraction, a lower percentage
of apoptotic cells was detected in the infarcted tissue at
2 days after intracoronary cell administration. Our data agree
with published studies demonstrating the in vivo anti-
apoptotic effect of ATMSCs.42,43 Furthermore, we described
an up-regulation of potential mechanisms related to this early
anti-apoptotic effect: an increase in circulating HGF was
detected 2 days after ATMSCs administration, as well as an
up-regulation of hepatocyte growth factor receptor and
extracellular signal–regulated kinase 1 in the infarcted tissue,
which are mediators of the HGF signaling pathway. HGF
benefits in myocardial infarction have been postulated
previously,44,45 and its secretion by ATMSCs has been
described5 and reinforced,46 but these previous studies did
not analyze the relationship between ATMSCs therapy and an
increase in systemic circulation of HGF in a clinically relevant
AMI model. In the animals receiving ATMSCs, we also
identified an up-regulation of the secreted frizzled-related
protein 2 gene, an anti-apoptotic mediator that is secreted by
MSCs and exerts cardiac protection.47 However, despite the
10% reduction in the apoptotic process observed at 2 days
post-AMI, this effect was not sufficient to reduce infarct size
or enhance left ventricular ejection fraction.
Although no reduction in scar size was observed by CMR,
histological analysis detected a higher ratio of type I/type III
collagen in the infarcted tissue at 60 days, suggesting the
establishment of a more mature and stiffer scar in the animals
treated with ATMSCs. In a knock-out MMP9 mouse model of
myocardial infarction, Voorhees et al48 reported that a stiffer
scar presented better ventricle mechanics, suggesting that a
stiffer scar could prevent ventricular dilation. Although the
stiffer scar observed in the ATMSCs-treated animals in our
study could suggest less susceptibility to infarcted ventricle
dilation or scar rupture, more detailed studies with longer
follow-up are needed to prove this hypothesis.
Limitations
In this study, we were unable to determine baseline CMR
before ATMSCs treatment because of the immediacy of the
intracoronary infusion protocol (15 minutes after AMI
Figure 9. Images from picrosirius red staining were obtained with circularly polarized light. Collagen type
I (red fibers) was more predominant in the scar from animals treated with ATMSCs than with collagen type
III (green fibers). Scale bars, 50 lm. ATMSCs indicates adipose tissue-derived mesenchymal stem cells.
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induction). A limitation of all animal studies is that caution is
needed when extrapolating experimental results to the clinic.
However, the pig is considered one of the most clinically
translatable large-animal models for the study of potential
therapies in the context of AMI. It has a coronary artery
anatomy and distribution similar to that of humans, along with
a minimal pre-existing coronary collateral flow.49 On the other
hand, cell labeling-tracking and counting is limited in a large
animal because it is methodologically complicated to analyze
the entire organ, and thus, we performed the analysis in
representative histological samples. Another limitation when
using a porcine model is that sedation is required to obtain
blood samples, and consequently, the blood sampling proto-
col was designed considering the risks of increased mortality
because of repeated sedations in the nearly days after AMI
induction.
Conclusions
In summary, intracoronary administration of allogeneic
ATMSC is a safe procedure and promotes the stimulation of
reparative pathways, as evidenced by better myocardial
vascularization and perfusion in our clinically relevant model
of reperfused AMI. Although the short-term mechanisms
triggered by delivered ATMSCs were insufficient to modify
infarct size and left ventricle function, the local and systemic
changes promoted by ATMSCs therapy suggest remarkable
assets for future heart regeneration strategies.
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